SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001837607-24-000063
Filing Date
2024-05-14
Accepted
2024-05-14 16:09:11
Documents
78
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aeon-20240331x10q.htm   iXBRL 10-Q 1389216
2 EX-31.1 aeon-20240331xex31d1.htm EX-31.1 16334
3 EX-31.2 aeon-20240331xex31d2.htm EX-31.2 15934
4 EX-32.1 aeon-20240331xex32d1.htm EX-32.1 8644
5 EX-32.2 aeon-20240331xex32d2.htm EX-32.2 8096
  Complete submission text file 0001837607-24-000063.txt   7845231

Data Files

Seq Description Document Type Size
6 EX-101.SCH aeon-20240331.xsd EX-101.SCH 73378
7 EX-101.CAL aeon-20240331_cal.xml EX-101.CAL 38273
8 EX-101.DEF aeon-20240331_def.xml EX-101.DEF 357505
9 EX-101.LAB aeon-20240331_lab.xml EX-101.LAB 541089
10 EX-101.PRE aeon-20240331_pre.xml EX-101.PRE 492748
82 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240331x10q_htm.xml XML 1267389
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40021 | Film No.: 24944367
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)